GHRP mimetic selective agonist

What is GHRP mimetic selective agonist?

A selective GH secretagogue peptide with relatively clean GH release profile in studied settings; limited outcome trials.

This profile is educational. It organizes publicly discussed research context for GHRP mimetic selective agonist and related naming aliases — it is not a treatment guide.

Proposed mechanism

Selective GHS-R1a agonism stimulating GH release with minimal effect on cortisol and prolactin compared to older GHRPs.

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Limited human evidence

Preclinical evidence grade: Moderate human evidence

Ipamorelin is among the most discussed selective GHRPs. Human studies confirm GH stimulation with favorable selectivity vs GHRP-6. Clinical outcome trials for body composition or recovery are sparse. WADA prohibited. Not FDA approved.

Key uncertainties

• Meaningful clinical outcomes in humans
• Long-term use effects

Research areas being studied

• GH axis research
• Recovery
• Sleep quality research

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

• Headache
• Injection-site reactions
• Mild water retention reported

Additional risks & considerations

• GH-axis perturbation
• Unregulated product quality
• WADA prohibited

Regulatory status

Not FDA-approved

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

References & sources

• Gobburu JVS et al. (1999). Ipamorelin, a selective growth hormone secretagogue — Eur J Endocrinol. Evidence type: human.